As sites of action for drugs used to treat schizophrenia and Parkinson s disease, dopamine receptors are among the most validated drug targets for neuropsychiatric disorders. Dopamine receptors are also drug targets or potential targets for other disorders such as substance abuse, depression, Tourette s syndrome, and attention deficit hyperactivity disorder. Updated from the successful first edition, "The Dopamine Receptors" serves as a reference work on dopamine receptors while also highlighting the areas of research that are most active today. To achieve this goal, authors have written chapters that set a broad area of research in its historical context, rather than focusing on the research output of their own laboratories. "
Or split into 4x interest-free payments of 25% on orders over R50
Learn more
As sites of action for drugs used to treat schizophrenia and Parkinson s disease, dopamine receptors are among the most validated drug targets for neuropsychiatric disorders. Dopamine receptors are also drug targets or potential targets for other disorders such as substance abuse, depression, Tourette s syndrome, and attention deficit hyperactivity disorder. Updated from the successful first edition, "The Dopamine Receptors" serves as a reference work on dopamine receptors while also highlighting the areas of research that are most active today. To achieve this goal, authors have written chapters that set a broad area of research in its historical context, rather than focusing on the research output of their own laboratories. "
Imprint | HumanaPress |
Country of origin | United States |
Series | The Receptors |
Release date | November 2009 |
Availability | Expected to ship within 10 - 15 working days |
First published | November 2009 |
Editors | Kim Neve |
Dimensions | 235 x 155 x 43mm (L x W x T) |
Format | Hardcover |
Pages | 648 |
Edition | 2nd ed. 2010 |
ISBN-13 | 978-1-60327-332-9 |
Barcode | 9781603273329 |
Categories | |
LSN | 1-60327-332-8 |